share_log

Arcutis Biotherapeutics | 10-Q: Q3 2024 Earnings Report

Arcutis Biotherapeutics | 10-Q: Q3 2024 Earnings Report

Arcutis Biotherapeutics | 10-Q:2024財年三季報
美股SEC公告 ·  2024/11/06 21:12

牛牛AI助理已提取核心訊息

Arcutis Biotherapeutics reported strong Q3 2024 financial results, with total revenue reaching $44.8 million, up from $38.1 million in Q3 2023. Product revenue surged to $44.8 million, primarily driven by ZORYVE cream 0.3% ($22.0 million), ZORYVE foam ($20.3 million), and the newly launched ZORYVE cream 0.15% ($2.5 million). The net loss narrowed to $41.5 million from $44.8 million year-over-year.Operating expenses increased to $83.8 million from $75.0 million in Q3 2023, with selling, general and administrative expenses rising to $58.8 million. Research and development costs decreased to $19.5 million from $26.2 million, reflecting the completion of Phase 3 studies. The company maintained a strong liquidity position with $331.2 million in cash, cash equivalents and marketable securities as of September 30, 2024.In October 2024, Arcutis made a partial debt prepayment of $100 million, reducing its outstanding loan balance to $100 million. The company expanded its commercial reach through a co-promotion agreement with Kowa Pharmaceuticals for primary care and pediatric markets, and received Health Canada approval for ZORYVE foam. Management expects continued growth driven by its expanded product portfolio and strategic partnerships.
Arcutis Biotherapeutics reported strong Q3 2024 financial results, with total revenue reaching $44.8 million, up from $38.1 million in Q3 2023. Product revenue surged to $44.8 million, primarily driven by ZORYVE cream 0.3% ($22.0 million), ZORYVE foam ($20.3 million), and the newly launched ZORYVE cream 0.15% ($2.5 million). The net loss narrowed to $41.5 million from $44.8 million year-over-year.Operating expenses increased to $83.8 million from $75.0 million in Q3 2023, with selling, general and administrative expenses rising to $58.8 million. Research and development costs decreased to $19.5 million from $26.2 million, reflecting the completion of Phase 3 studies. The company maintained a strong liquidity position with $331.2 million in cash, cash equivalents and marketable securities as of September 30, 2024.In October 2024, Arcutis made a partial debt prepayment of $100 million, reducing its outstanding loan balance to $100 million. The company expanded its commercial reach through a co-promotion agreement with Kowa Pharmaceuticals for primary care and pediatric markets, and received Health Canada approval for ZORYVE foam. Management expects continued growth driven by its expanded product portfolio and strategic partnerships.
Arcutis Biotherapeutics公佈了2024年第三季度強勁的財務報告,總營業收入達到4480萬美元,較2023年第三季度的3810萬美元有所增長。產品營業收入飆升至4480萬美元,主要得益於ZORYVE 0.3%乳膏(2200萬美元)、ZORYVE泡沫(2030萬美元)以及新推出的ZORYVE 0.15%乳膏(250萬美元)。淨虧損從去年同期的4480萬美元縮減至4150萬美元。營業費用從2023年第三季度的7500萬美元增加至8380萬美元,其中銷售、一般和行政費用上升至5880萬美元。研發費用從2620萬美元減少至1950萬美元,反映了三期研究的完成。截至2024年9月30...展開全部
Arcutis Biotherapeutics公佈了2024年第三季度強勁的財務報告,總營業收入達到4480萬美元,較2023年第三季度的3810萬美元有所增長。產品營業收入飆升至4480萬美元,主要得益於ZORYVE 0.3%乳膏(2200萬美元)、ZORYVE泡沫(2030萬美元)以及新推出的ZORYVE 0.15%乳膏(250萬美元)。淨虧損從去年同期的4480萬美元縮減至4150萬美元。營業費用從2023年第三季度的7500萬美元增加至8380萬美元,其中銷售、一般和行政費用上升至5880萬美元。研發費用從2620萬美元減少至1950萬美元,反映了三期研究的完成。截至2024年9月30日,公司保持了強勁的流動資金狀況,現金、現金等價物和可交易證券總計達到33120萬美元。2024年10月,Arcutis進行了10000萬美元的部分債務提前償還,將未償還貸款餘額減少至1億美元。公司通過與Kowa Pharmaceuticals簽署的共同推廣協議,擴大了其在初級醫療和兒童市場的商業覆蓋,並獲得了加拿大衛生部對ZORYVE泡沫的批准。管理層預計將繼續實現增長,這得益於其擴展的產品組合和戰略伙伴關係。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 221

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。